$42,000 Grant from NIDA to Open Medicine Foundation (OMF) for “Quick-to-Patient” Pilot Trial:
Thanks to our generous community, NIDA has granted the Open Medicine Foundation (OMF) $42,000 towards a 100 patient pilot for studying the benefits of Vitamin B12 and Methyl Folate supplementation and the MTHFR gene mutations commonly found in ME/CFS patients.
MTHFR (Methyltetrahydrofolate Reductase) is a gene that is directly involved in the methylation of two key vitamins, B12 and Folic Acid. Regardless of serum levels, both vitamins must be chemically converted to their active forms before they can be effectively utilized. Once methylated, they are critical cofactors in other downstream metabolic reactions that are intimately involved with energy production, neuromuscular and cognitive homeostasis. The mutations seem to occur with a far greater frequency in patients with ME/CFS and other neuroimmune diseases compared with the general population.
These deficiencies may be managed by alternative forms of Vitamin B12 and Folate. This study will test the benefits of supplementing with Methyl B12 and Methyl Folate in ME/CFS patients with and without the MTHFR gene mutations.